The relationship between radiofrequency-electromagnetic radiation from cell phones and brain tumor: The brain tumor incidence trends in South Korea

Trends, age shifts, and potential delayed peaks post-pandemic of early-onset brain and central nervous system cancers in individuals aged 20-49: a cross-sectional study

BACKGROUND

Central nervous system (CNS) cancers are highly lethal and increasingly affect younger populations aged 20-49, posing significant challenges to global healthcare systems. Current research on early-onset CNS cancer trends is limited and outdated, with uncertain impacts from the COVID-19 pandemic. This study explores the epidemiology of early-onset CNS cancer and the pandemic's effects.

METHODS

We analyzed incidence, mortality, and disability-adjusted life years (DALYs) rates for early-onset CNS cancer (age 20-49) from 2019 to 2021 using GBD 2021 data. The global data were categorized into five regions based on the Socio-Demographic Index (SDI), reflecting income, education, and fertility rates. Trends over the past 30 years were examined using estimated annual percentage change (EAPC), average annual percentage change (AAPC), and joinpoint analysis, with a focus on 2019-2021. The Bayesian age-period-cohort (BAPC) model predicted post-pandemic impacts on CNS cancer metrics.

RESULTS

In 2021, global cases of early-onset CNS cancer rose to 50 201.7 (95% UI, 42 864.1-58 187.5), with deaths increasing to 25 023.1 (95% UI, 20 973.8-29 670.8) and DALYs reaching 1 483 019.4 (95% UI, 1 240 923.4-1 756 043.3). The incidence rate increased to 2.1 (95% UI, 1.8-2.5), while mortality rates remained stable at 1.1 (95% UI, 0.9-1.2), and DALY rates decreased to 62.6 (95% UI, 52.4-74.1). Over the past two decades, the incidence of early-onset CNS cancer has steadily increased, particularly in regions with a high SDI and in emerging economies. Although there was a decline in early-onset CNS cancer-related metrics during the pandemic, it is anticipated that global incidence rates will peak between 2035 and 2040.

CONCLUSION

This study provides a comprehensive overview of early-onset CNS cancer trends. Despite stable mortality rates, the increasing incidence suggests a growing global burden, with a delayed peak expected due to the pandemic. These findings highlight the need for preventive and control policies targeting early-onset CNS cancer.

Assessment of the potential threats to brain health posed by the radiation from 5G sub-6 GHz base stations in China using dosimetric methods

The 5G sub-6 GHz radio frequency (RF) electromagnetic fields (EMF) are the most widely used in China's communications. The public has expressed concerns about possible brain health effects of the higher frequency bands in 5G compared to 2G, 3G, and 4G bands. It is imperative to empirically investigate the potential health hazards of these novel frequency bands in 5G communication technology. This study evaluates the assessment of brain tissue dose coupling from sub-6 GHz band EMF emitted by base stations in China. Based on the 3D virtual human body model, the simulation environment was established. Dose including specific absorption rate (SAR) and internal electric field (IEF) between 2G, 3G, and 4G bands and 5G sub-6 GHz was investigated using normalized exposure values and exposure limits. The results indicate that the sub-6 GHz high-frequency band of 5G has the lowest dose value. It can be concluded that high-frequency electromagnetic radiation in 5G sub-6 GHz reduces the dose and health threats to the brain. This provides strong support for the promotion of 5G commutation in China and other regions.

Ocular Motor Cranial Nerve Palsies and Increased Risk of Primary Malignant Brain Tumors: South Korean National Health Insurance Data

The aim of this study was to investigate the association between ocular motor cranial nerve palsies (OMCNP) and the occurrence of primary malignant brain tumors in a Korean population, using the national sample cohort database from Korea National Health Insurance Service (KNHIS). KNHIS data between 2010 and 2017 were analyzed. Our sample encompassed 118,686 participants, including 19,781 from a recently diagnosed OMCNP cohort and 98,905 from a matched control cohort through a 1:5 propensity score matching based on age and gender. To counteract the issue of reverse causation, we integrated a one-year time lag in our sensitivity analysis. Study participants were followed up until 31 December 2019. Cox proportional hazard regression analysis was used to compute the adjusted hazard ratio (HR) for primary malignant brain tumors according to the OMCNP diagnosis. Additionally, we performed a subgroup analysis to discern effects of various factors on the association between OMCNP and primary malignant brain tumors. HR for primary malignant brain tumors was 3.272 (95% confidence interval [CI]: 2.294 to 4.665) in the OMCNP cohort compared to the control cohort in a fully adjusted model for age, sex, socio-economic status, smoking, drinking, regular physical exercise, hypertension, diabetes, dyslipidemia, obesity, chronic kidney disease, and human immunodeficiency virus infection. Further subgroup analysis revealed that the risk of primary malignant brain tumors was significantly increased in women with OMCNP compared to men with OMCNP (HR: 5.118 in women vs. 2.441 in men, p = 0.0440), and in those aged <65 years than in those aged ≥65 years (HR: 6.951 in age < 65 years vs. 1.899 in age ≥ 65 years, p = 0.0006). Our population-based cohort study demonstrated a significantly increased risk of subsequent primary malignant brain tumors in patients with OMCNP. Particularly, OMCNP-afflicted women aged below 65 manifested a heightened probability of developing primary malignant brain tumors compared to those devoid of OMCNP.